These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15578665)

  • 21. [Survey on the threshold for platelet transfusions].
    Hiruma K; Okuyama Y; Osaka A; Kasai M; Kodo H; Takamoto S; Handa M; Fujii H; Muto Y; Mori M; Shimizu M
    Rinsho Ketsueki; 2004 Nov; 45(11):1187-92. PubMed ID: 15609685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why has the demand for platelet components increased? A commentary.
    Greinacher A; Hoffmann W
    Transfus Med; 2014 Oct; 24(5):257-9. PubMed ID: 25327285
    [No Abstract]   [Full Text] [Related]  

  • 23. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions.
    Blumberg N; Gettings KF; Turner C; Heal JM; Phipps RP
    Transfusion; 2006 Oct; 46(10):1813-21. PubMed ID: 17002639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
    Kim YR; Kim JS; Cheong JW; Song JW; Min YH
    Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Thrombocytopenia: is therapeutic platelet transfusion effective? Prophylactic platelet transfusion remains justified].
    Bethge W
    Dtsch Med Wochenschr; 2012 Dec; 137(50):2630. PubMed ID: 23225185
    [No Abstract]   [Full Text] [Related]  

  • 26. [Updated approaches to erythrocyte and platelet transfusions in children].
    Agranenko VA
    Gematol Transfuziol; 1996; 41(2):41-3. PubMed ID: 8754161
    [No Abstract]   [Full Text] [Related]  

  • 27. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor.
    McPherson ME; Anderson AR; Haight AE; Jessup P; Castillejo MI; Hillyer CD; Josephson CD
    Transfusion; 2009 Sep; 49(9):1977-86. PubMed ID: 19453984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic platelet transfusion for hypoproliferative thrombocytopenia.
    Tsuda K; Morita T; Tsubokura M; Matsumura T; Kami M
    Lancet; 2013 Mar; 381(9868):723-4. PubMed ID: 23472914
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic platelet transfusion for hypoproliferative thrombocytopenia.
    Takahashi Y; Nishikawa Y; Mori J; Hamaki T; Tanimoto T
    Lancet; 2013 Mar; 381(9868):724. PubMed ID: 23472915
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic platelet transfusion for hypoproliferative thrombocytopenia - authors' reply.
    Wandt H; Schaefer-Eckart K
    Lancet; 2013 Mar; 381(9868):724. PubMed ID: 23472916
    [No Abstract]   [Full Text] [Related]  

  • 31. Expanding the role of umbilical cord blood transplantation.
    Brunstein CG; Setubal DC; Wagner JE
    Br J Haematol; 2007 Apr; 137(1):20-35. PubMed ID: 17359369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two novel challenges in platelets: Potential cause of transfusion failures in onco-hematologic patients versus success in eye regenerative medicine.
    Seghatchian J
    Transfus Apher Sci; 2017 Oct; 56(5):755. PubMed ID: 28928024
    [No Abstract]   [Full Text] [Related]  

  • 33. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation.
    de Boer MT; Christensen MC; Asmussen M; van der Hilst CS; Hendriks HG; Slooff MJ; Porte RJ
    Anesth Analg; 2008 Jan; 106(1):32-44, table of contents. PubMed ID: 18165548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
    Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
    Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shifting ground and gaps in transfusion support of patients with hematological malignancies.
    Cserti-Gazdewich C
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):553-560. PubMed ID: 30504357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
    Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
    Transfusion; 2005 Jul; 45(7):1064-72. PubMed ID: 15987349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why has demand for platelet components increased? A review.
    Estcourt LJ
    Transfus Med; 2014 Oct; 24(5):260-8. PubMed ID: 25327286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation.
    Briggs C; Hart D; Kunka S; Oguni S; Machin SJ
    Transfus Med; 2006 Apr; 16(2):101-9. PubMed ID: 16623916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the economic value of the INTERCEPT blood system in Belgium.
    Moeremans K; Warie H; Annemans L
    Transfus Med; 2006 Feb; 16(1):17-30. PubMed ID: 16480436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy.
    Chaoui D; Chakroun T; Robert F; Rio B; Belhocine R; Legrand O; Salanoubat C; Lecrubier C; Casadevall N; Marie JP; Elalamy I
    Transfusion; 2005 May; 45(5):766-72. PubMed ID: 15847667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.